A patient has poor corrected count increments after two ABO-compatible platelet transfusions. Fever, bleeding, DIC, and splenomegaly are excluded, and strong HLA class I antibodies are detected. Which product strategy is most appropriate?

• 1 Continue random donor platelets without antibody screening or monitoring for reactions
• 2 Use washed red blood cells instead of platelets to avoid HLA antibodies
• 3 Select only RhD-negative plasma products to reduce alloimmunization risk
• 4 Provide compatible platelets selected by HLA matching or antibody specificity ✓ 정답

학습 참고용입니다. 실제 임상은 최신 지침과 소속 기관 프로토콜을 따르세요.